STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior...
Transcript of STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior...
![Page 1: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/1.jpg)
PROSTATE:
STRATEGIES FOR TREATMENT (DE)ESCALATION
Anders Widmark,
Professor, Senior Consultant
Department of Radiation Sciences,
Oncology, CancerCenter
Umeå University
![Page 2: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/2.jpg)
DISCLOSURE
• I have no disclosure
• “The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of Accuray Incorporated or its subsidiaries. No official endorsement by Accuray Incorporated or any of its subsidiaries of any vendor, products or services contained in this presentation is intended or should be inferred.”
• An honorarium is provided by Accuray for this presentation
![Page 3: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/3.jpg)
• Dose-escalation – 2 Gy x 32=64 Gy
• Conventional fractionation o 2 Gy x 39 = 78 Gy
• Moderate HYPO fractionationo 2.4−3.4 Gy, 20 fractions
o 4 randomised trials
o
• ULTRA HYPO fractionation o 5–10 Gy per fraction x 4–7 fractions
o HYPO-RT-PC
• SBRT- Stereotactic Body RadioTherapyo 5–10 Gy per fraction x 4–7 fractions
o non-randomised trials Outcome and Toxicity
AGENDA
![Page 4: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/4.jpg)
Is there a Patient Benefit?
HDR Bracy is common in high risk
in Sweden
Dose Escalation Radiotherapy of
Prostate Cancer
Onk. AW 0204
![Page 5: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/5.jpg)
Randomised Studies
Dose-escalation RadiotherapyMD Andersson (n=304)
– 70 Gy v.s. 78 Gy
Holland ( Rotterdam, Amsterdam)
– 68 Gy v.s. 78 Gy n=650? (Closed)
MRC (England)
– 64 Gy v.s. 74 Gy n=800 Closed
France (Prof Bey, Nancy et al)
– 70 Gy vs. 78 Gy (200 closed)
Berlin (Charite)
– 76 Gy vs. 82 Gy (200??)
NUS, Onk. AW 9811
![Page 6: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/6.jpg)
Dose-escalation
Lancet Oncol 2014; 15: 464–73
Treatment data were obtained on more than 20,000 patients in
the National Oncology Data Alliance®, a, proprietary database of merged
tumor registries, who were treated for prostate cancer with definitive radiotherapy
between 1995 and 2006. M. Follow up 8 Years.
Md. OS
11.4 y.
12.0 y.
12.8 y.
![Page 7: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/7.jpg)
• Convenient to patients
• Competitive to radical prostatectomy
• Cost effective
• A way to increase the biological dose
• Iso-toxic
• More efficient
• May avoid hormones
?
Why hypofractionation?
![Page 8: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/8.jpg)
HYPOFRACTIONATION
ISSUES
• If prostate cancer α/β is low, higher effect is expected, with FEW but higher dose/fraction (Enhanced Tumor Control Probability).
• BUT Small doses per fraction saves late responding (normal) tissue,
• So if large dose/fraction, we must reduce MARGINS WHICH REQUIRES GOOD POSITIONING
• BUT
• Reducing margins really need PRECICION radiotherapy, since missing the tumor is devastating, due to the high dose per fraction
![Page 9: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/9.jpg)
α/β for prostate cancer!
KingWang
Hyper
Valdagni
B&R
NahumDasu A, 2007
Prostate alpha/beta revisited – an analysis of clinical results
from 14 168 patients,
Patients: Conventional Fractionation (CF) 11330 – HYPO 2838
“The analysis of hypofractionation data led to very low a/b values (1–1.7
Gy)”
Dasu A, Toma-Dasu I 2012
α/β < 3.0
Tumour α/β =10.0
Prostate
![Page 10: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/10.jpg)
30 40 50 60 70 80 900
20
40
60
80
100
Fowler, Ritter, Chappell & Brenner "What hypofr protocols..." IJROBP 2003 56(4):1093-1194.
30F
i.e. 69% to 85%
190 x 2 pats
Using 15F x 3.6Gy with no change in physical technique should give
same late complic's but increased bNED as if 72Gy increased to 80Gy,
Assuming prostate
tumor = 1.5 Gy
(3Gy)Constant late BED equiv to 72 Gy NTD
36Fx 2Gy
3F 5F
7.12
Gy
10F
4.69
Gy
15F
3.62
Gy
20F
3.0
Gy
25F
2 Gy fractions
Prostate Ca Intermediate Risk 10-20 ng/ml
Actu
ari
al 5
y
bN
ED
%
Total dose (Gy)
![Page 11: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/11.jpg)
MODERAT-HYPO-FRACTION TRIALS
Dearnaley & Hall 2017
IM
IM + High
IM
LR
2.5-4 Gy / Fraction
Hormones, 6m
Hormones 32m
![Page 12: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/12.jpg)
1 2 3 4 5 6 7 8 9 10 α/β
The “real prostate cancer α/β”
Lukka
Arcangeli
DearnaleyCHHiP
LeeRTOG 0415
IncrocciHYPRO
*
*
*Pollack
Yeoh
![Page 13: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/13.jpg)
ULTRA-HYPOFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED
RADIOTHERAPY FOR PROSTATE CANCER:
5-YEAR OUTCOMES OF THE HYPO-RT-PC
RANDOMISED, NON-INFERIORITY, PHASE 3 TRIAL
Anders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, Camilla Thellenberg-
Karlsson, Morten Hoyer, Magnus Lagerlund, Jon Kindblom, Claes Ginman, Bengt
Johansson, Kirsten Björnlinger, Mihajl Seke, Måns Agrup, Per Fransson, Björn Tavelin,
David Norman, Björn Zackrisson, Harald Anderson, Elisabeth Kjellén,
Lars Franzén, Per Nilsson
Umeå, Lund, Sundsvall, Kalmar, Göteborg, Karlstad, Örebro, Växjö, Jönköping, Linköping, Sweden
and Århus, Denmark
The Lancet Published Online June 18, 2019
![Page 14: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/14.jpg)
• Open, randomised,phase III trial
o Intermediate/high-risk prostate cancer*
o 1200 patients accrued
▪ July 2005-Nov 2015
o No androgen deprivation therapy
MATERIAL AND METHODS − TRIAL DESIGN
RANDOMISE
Conventional fractionation (CF): 39∗2.00 Gy = 78.0 Gyover 8 weeks
Ultrahypofractionation(U-HF): 7∗6.10 Gy = 42.7 Gyover 2.5 weeks
Equieffective for late normal tissue
complication probability (α/β=3 Gy)
*T1c-T3a, PSA ≤20 with one or two of the following risk factors; T3a or Gleason ≥7 or PSA >10
![Page 15: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/15.jpg)
• Primary endpoint
o Time to biochemical* or clinical (local/distant) failure
• Secondary endpoints
o Overall survival
o Cancer specific survival
o Side effects (RTOG scale)
o Quality of Life (QoL)
o Time to change of treatment
o PSA response rate
• Trial design/statistics
o Non-inferiority
o Primary endpoint evaluated with Cox proportional hazards model
o Pre-specified critical HR of1.338 → ∆=4% margin
MATERIAL AND METHODS −
ENDPOINTS/STATISTICS
*PSA nadir + 2.0 ng/ml
![Page 16: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/16.jpg)
• Target volumeso CTV = prostate
▪ SV not included
o PTV=CTV + 7 mm isotropic margino CTV delineated on CT
▪ with MR guidance
• RT techniqueo 3D-CRT (80%)o IMRT/VMAT (20%)
• IGRTo implanted fiducial markers
• OAR constraints/objectiveso Rectum: V90%≤ 15%, V75%≤ 35%,
V65%≤ 45%o Bladder: none
MATERIAL AND METHODS − RADIOTHERAPY
7 mm
![Page 17: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/17.jpg)
BASELINE DEMOGRAPHICS, CLINICAL
CHARACTERISTICS, AND RADIOTHERAPY DETAILS
FOR THE PER-PROTOCOL POPULATION
![Page 18: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/18.jpg)
FAILURE-FREE SURVIVAL
FFS
84%
![Page 19: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/19.jpg)
OVERALL SURVIVAL
![Page 20: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/20.jpg)
SIDE EFFECTS
Physician
Urinary Toxicity
Patient
![Page 21: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/21.jpg)
Physician
Bowel Toxicity
Patient
![Page 22: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/22.jpg)
Physician
Erectal Function
Patient
![Page 23: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/23.jpg)
CUMULATIVE INCIDENCE OF PHYSICIAN-
REPORTED LATE URINARY AND BOWEL TOXICITY
OF GRADE 2 OR WORSE
Urinary Bowel
![Page 24: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/24.jpg)
INTERPRETATION - CONCLUSION
• Ultra-hypofractionated radiotherapy is non-inferior to conventionally fractionated radiotherapy for intermediate-to-high risk prostate cancer regarding failure-free survival.
• Early side-effects, at end of treatment, are more pronounced with ultra-hypofractionation compared with conventional fractionation whereas late toxicity is similar in both treatment groups.
• The results support the use of ultra-hypofractionation for radiotherapy of prostate cancer.
![Page 25: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/25.jpg)
1 2 3 4 5 6 7 8 9 10 α/β
The “real prostate cancer α/β”
Lukka
Arcangeli
DearnaleyCHHiP
LeeRTOG 0415
IncrocciHYPRO
*
*
*Pollack
Yeoh
HYPO-RT-PC
![Page 26: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/26.jpg)
ULTRA-HYPOFRACTIONATION TRIALS
Morgan et. al. JCO 2018
![Page 27: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/27.jpg)
62 Gy in 20fr
![Page 28: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/28.jpg)
FIGURE 2: ACUTE RADIATION THERAPY ONCOLOGY GROUP TOXICITY FOR
GASTROINTESTINAL (A) AND GENITOURINARY (B) SYSTEMS
![Page 29: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/29.jpg)
Incontinence Obstructive subdomain Overall urinary bother
Bowel subdomain Sexual subdomain Hormonal subdomain
![Page 30: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/30.jpg)
QUESTIONS?
COMMENTS?
![Page 31: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/31.jpg)
![Page 32: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/32.jpg)
![Page 33: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/33.jpg)
HYPO ARGUMETS
![Page 34: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/34.jpg)
ACUTE TOX - URINARYRTOG HYPO-RT-PC RTOG – PACE-B PROM HYPO-RT-PC
![Page 35: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/35.jpg)
ACUTE TOX - BOWELPROM HYPO-RT-PCRTOG – PACE-B
![Page 36: STRATEGIES FOR TREATMENT (DE)ESCALATION · 2020. 2. 7. · Anders Widmark, Professor, Senior Consultant Department of Radiation Sciences, Oncology, CancerCenter Umeå University.](https://reader036.fdocuments.us/reader036/viewer/2022071419/61184b8f30dc265cda39222b/html5/thumbnails/36.jpg)